System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 41852722 DOI: 10.1016/j.isci.2026.115081

CMV seropositivity associates with poor clinical outcome in triple negative breast cancer.

iScience 29(3):115081

Authors: Romain-David Seban, Constance Lamy, Luc Cabel, Hugo Roux, Ines Dias Da Silva, Lounes Djerroudi, Doriane Gorret, Ana Inès Lalanne, Delphine Louis, Maud Milder, Fabien Reyal, Enora Laas, Claire Bonneau, Nicolas Pouget, Marie-Paule Sablin, Jean-Yves Pierga, Celia Dupain, Frédérique Berger, Irène Buvat, François-Clément Bidard, Anne Vincent-Salomon, Christophe Le Tourneau, Cécile Alanio, Olivier Lantz

Affiliations

  • Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, Paris, France.
  • Laboratory of Translational Imaging in Oncology, Paris Sciences et Lettres University (PSL) Research University, Institut Curie, Orsay, France.
  • Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.
  • Department of Medical Oncology, Paris and Saint-Cloud Institut Curie, Paris, France.
  • Circulating Tumor Biomarkers Laboratory, Inserm CIC2501, Institut Curie, Paris, France.
  • INSERM U932, PSL University, Institut Curie, 75005 Paris, France.
  • Clinical Immunology Laboratory, Institut Curie, Paris, France.
  • Centre d'investigation Clinique INSERM CIC2501, Institut Curie, Paris, France.
  • Data Department, Institut Curie, Paris, France.
  • PSL University, Institut Curie Hospital, Department of Surgery, 75005 Paris, France.
  • Service of Breast and Gynecologic Surgery, Institut Curie, Paris, France.
  • Institut Curie - Saint Cloud, Surgical Oncology Department, 35, rue Dailly, 92210 Saint-Cloud, France.
  • U1331, STAMPM Team, Saint-Cloud, France.
  • Université Paris Cité, Paris, France.
  • Biometry Unit, Institut Curie, PSL University, Saint-Cloud, Paris, France.
  • Institut Curie, Université PSL, Inserm, U1288 LITO, Orsay, France.
  • UVSQ, Paris-Saclay University, Gif-sur-Yvette, France.
  • Department of Pathology, Institut Curie, Paris-Sciences-Lettres Research University, Paris, France.
  • Université Paris Cité, INSERM, PARCC, 75015 Paris, France.

Abstract

Cytomegalovirus (CMV) infection modifies immune fitness and T cell subset distribution in healthy donors. We analyzed a recent prospective cohort of 240 patients bearing triple-negative breast cancer for CMV serology status and T cell subsets and assessed recurrence-free survival (RFS) and overall survival (OS). CMV seropositivity was significantly associated with worse RFS (HR = 2.6, 95%CI = 1.2-5.7) and OS (HR = 3.0, 95%CI = 1.2-7.4) in multivariable analyses. A prognostic model incorporating CMV status alongside tumor and nodal stage improved risk stratification. The impact of CMV status was not confirmed in another less well characterized, more ancient cohort (n = 507), probably related to the different therapeutic strategies used in the early 2000s. CMV status had a strong impact on T cell subset distribution with increased frequency of effector CD8 T cells and decreased proportion of Tregs. The impact of CMV infection on cancer patient survival remains to be determined during chemo-immunotherapy, which is now the standard of care.

MeSH

Cells, Triple Negative Breast Neoplasms, Breast Neoplasms, Neoplasms, Breast, T-Lymphocyte Subsets, Infections